Clinical Trial Update: Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of Envafolimab and Lenvatinib with TACE for unresectable locally advanced hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Envafolimab (envafolimab)
• Lenvatinib (lenvatinib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Objective Response Rate (ORR) | Phase 2 | Status: UNKNOWN